Literature DB >> 21868818

The effects of implementation of the Surviving Sepsis Campaign in the Netherlands.

M Tromp1, D H T Tjan, A R H van Zanten, S E M Gielen-Wijffels, G J D Goekoop, M van den Boogaard, C M Wallenborg, H S Biemond-Moeniralam, P Pickkers.   

Abstract

To reduce unintentional and avoidable adverse events in patients in hospitals in the Netherlands, a patient safety agency (VMS) programme was launched in 2008. Among the VMS topics, the programme 'optimal therapy in severe sepsis', according to the international Surviving Sepsis Campaign (SSC), aims to improve early diagnosis and treatment of sepsis to reduce sepsis mortality by 15% before the end of 2012. We analysed compliance data submitted to the international SSC database from the Netherlands and compared these data with published international SS C results. Data of 863 patients, representing 6% of the international data (n=14,209), were used for analysis. In the Netherlands, the resuscitation bundle compliance improved significantly from 7% at baseline to 27% after two years (p=0.002). Internationally, the resuscitation bundle compliance increased significantly from 11 to 31% (p.

Entities:  

Mesh:

Year:  2011        PMID: 21868818

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  8 in total

1.  [Sepsis detection in emergency medicine : Results of an interprofessional survey on sepsis detection in prehospital emergency medicine and emergency departments].

Authors:  C Metelmann; B Metelmann; C Scheer; M Gründling; B Henkel; K Hahnenkamp; P Brinkrolf
Journal:  Anaesthesist       Date:  2018-05-25       Impact factor: 1.041

Review 2.  Disseminated intravascular coagulation: a review for the internist.

Authors:  Marcel Levi; Tom van der Poll
Journal:  Intern Emerg Med       Date:  2012-09-27       Impact factor: 3.397

3.  Recognition of sepsis in primary care: a survey among GPs.

Authors:  Feike J Loots; Roeland Arpots; Rick van den Berg; Rogier M Hopstaken; Paul Giesen; Marleen Smits
Journal:  BJGP Open       Date:  2017-05-03

4.  New clinical prediction model for early recognition of sepsis in adult primary care patients: a prospective diagnostic cohort study of development and external validation.

Authors:  Feike J Loots; Marleen Smits; Rogier M Hopstaken; Kevin Jenniskens; Fleur H Schroeten; Ann van den Bruel; Alma C van de Pol; Jan Jelrik Oosterheert; Hjalmar Bouma; Paul Little; Michael Moore; Sanne van Delft; Douwe Rijpsma; Joris Holkenborg; Bas Ct van Bussel; Ralph Laven; Dennis Cjj Bergmans; Jacobien J Hoogerwerf; Gideon Hp Latten; Eefje Gpm de Bont; Paul Giesen; Annemarie den Harder; Ron Kusters; Arthur Rh van Zanten; Theo Jm Verheij
Journal:  Br J Gen Pract       Date:  2022-05-26       Impact factor: 6.302

5.  Appropriate empirical antibiotic use in the emergency department: full compliance matters!

Authors:  Marvin A H Berrevoets; Jaap Ten Oever; Jacobien Hoogerwerf; Bart Jan Kullberg; Femke Atsma; Marlies E Hulscher; Jeroen A Schouten
Journal:  JAC Antimicrob Resist       Date:  2019-11-13

6.  Integrating sepsis management recommendations into clinical care guidelines for district hospitals in resource-limited settings: the necessity to augment new guidelines with future research.

Authors:  Shevin T Jacob; Matthew Lim; Patrick Banura; Satish Bhagwanjee; Julian Bion; Allen C Cheng; Hillary Cohen; Jeremy Farrar; Sandy Gove; Philip Hopewell; Christopher C Moore; Cathy Roth; T Eoin West
Journal:  BMC Med       Date:  2013-04-18       Impact factor: 8.775

7.  Another step in improving the diagnosis of disseminated intravascular coagulation in sepsis.

Authors:  Marcel Levi
Journal:  Crit Care       Date:  2013-08-23       Impact factor: 9.097

8.  Management of sepsis in out-of-hours primary care: a retrospective study of patients admitted to the intensive care unit.

Authors:  Feike J Loots; Marleen Smits; Carlijn van Steensel; Paul Giesen; Rogier M Hopstaken; Arthur R H van Zanten
Journal:  BMJ Open       Date:  2018-09-17       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.